I note that enrolment was planned to be from January to September 2016 but that current enrolment is short of the target of 10,000 and therefore presumably ongoing. It would be helpful to clarify the anticipated dates of enrolment, along with the expected dates of data cleaning and analysis. It is worth noting that BMJ Open guidelines state that manuscripts will not be considered if data collection is complete.
Publication of a protocol provides a good opportunity to inform the relevant communities of ongoing research but the most useful function is to clearly state the planned analysis. Observational studies are often undermined by poorly planned analysis, with no clear rationale for the hypotheses tested and no clear indication whether they were specified a priori or post hoc. The analysis described in this protocol currently represents a missed opportunity. It outlines in general terms the statistical approaches planned but does not relate the planned analysis to the stated objectives or say which hypotheses are to be tested. I recommend rewriting the analysis section to provide a clear statistical analysis plan. This should show how the analysis will address each objective, provide a rationale for each hypothesis tested and specify as precisely as possible the analysis that will be undertaken.
The number of hypothesis tests should be kept to a minimum and adjustment for multiple comparisons planned if multiple hypotheses are to be tested.
I recommend doing this before any analysis is undertaken. The analysis presented in table 4 should be removed. By including hypothesis tests it goes beyond presenting baseline data and involves presenting results, which BMJ Open guidance states should not be included in a protocol.
In fact I would consider the analysis presented in table 4 to be exactly the sort of analysis that the publication of protocol papers is intended to discourage. It involves multiple hypothesis tests comparing variables between rural and urban hospitals with no obvious a priori rationale and with any adjustment for multiple comparisons. Observational data could be used to compare urban and rural hospitals but the comparison needs to be carefully planned a priori to avoid drawing misleading conclusions.
The following additional issues could be addressed in a detailed statistical analysis plan:
1. Patients can have multiple entries in the study if presenting more than 30 days after initial enrolment, so how will multiple enrolments by the same patient be handled in analysis, bearing in mind that data from multiple enrolments by the same patient will be correlated? 2. Continuous variables, such as heart rate and blood pressure are likely to have non-linear associations with outcome. It would be wise to pre-specify how these variables will be analysed and consider categorising them prior to analysis. 3. The development of a usable risk-prediction model is likely to involve incorporation of clinical judgement, for example in deciding whether a predictor variable has a clinically credible association or one that is highly dependent on referral pathways. It would be worth planning in advance how clinical judgement will be used in the development of risk prediction models.
I realise that there is little opportunity to change the study design at this stage but it would be worth considering the potential impact of limiting inclusion to those providing informed consent. Is this restriction really necessary? Would it be possible for members of the care team to collect anonymised data? The study does not appear to involve changing patient care, so if it could be designed without the need to use personal identifiable data then it could be ethically undertaken without requiring patient consent, especially if information about the study and the opportunity to opt out were made available. Exclusion of those unable or unwilling to provide informed consent could be a significant limitation since these people are likely to be systematically different to those able and willing to provide consent.
VERSION 1 -AUTHOR RESPONSE
Comment 1: I note that enrollment was planned to be from January to September 2016 but that current enrollment is short of the target of 10,000 and therefore presumably ongoing. It would be helpful to clarify the anticipated dates of enrollment, along with the expected dates of data cleaning and analysis. It is worth noting that BMJ Open guidelines state that manuscripts will not be considered if data collection is complete.
Response: We thank the reviewer for the careful review. Please excuse us for not explaining the enrollment period clearly. The beginning dates of enrollment in 22 centers were not the same, but were distributed from January to September 2016. In addition, the enrollment duration has been planned to be 12 months at each hospital, so the entire period of implementation of patient enrollment was from January 2016 to September 2017. Furthermore, the follow-up is to be made at 30 days after presenting to the EDs, and data collection will not be completed until the end of October 2017. The expected dates of data cleaning will be completed at the end of December 2017. We have revised the description for patient enrollment highlighted in red in the Methods section of the manuscript.
Comment 2: Publication of a protocol provides a good opportunity to inform the relevant communities of ongoing research but the most useful function is to clearly state the planned analysis. Observational studies are often undermined by poorly planned analysis, with no clear rationale for the hypotheses tested and no clear indication whether they were specified a priori or post hoc. The analysis described in this protocol currently represents a missed opportunity. It outlines in general terms the statistical approaches planned but does not relate the planned analysis to the stated objectives or say which hypotheses are to be tested. I recommend rewriting the analysis section to provide a clear statistical analysis plan. This should show how the analysis will address each objective, provide a rationale for each hypothesis tested and specify as precisely as possible the analysis that will be undertaken. The number of hypothesis tests should be kept to a minimum and adjustment for multiple comparisons planned if multiple hypotheses are to be tested.
Response: We thank the reviewer for the advice. The core motivation for this initiative is to correlate hospital performance measures for evaluation and treatment with 30-day outcomes in ED patients with acute chest pain and suspected ACS. To achieve this, the primary analysis will be simple correlations of performance measures, now defined in the protocol document (table 3) with the rates of observed clinical outcomes at each of the 22 hospitals. Validation of the correlation of these measures with outcomes will facilitate the implementation of these measures into ongoing monitoring of practice and outcome. Accordingly, we have rewritten the statistical analysis plan in the revised manuscript.
Comment 3: I recommend doing this before any analysis is undertaken. The analysis presented in table 4 should be removed. By including hypothesis tests it goes beyond presenting baseline data and involves presenting results, which BMJ Open guidance states should not be included in a protocol. In fact I would consider the analysis presented in table 4 to be exactly the sort of analysis that the publication of protocol papers is intended to discourage. It involves multiple hypothesis tests comparing variables between rural and urban hospitals with no obvious a priori rationale and with any adjustment for multiple comparisons. Observational data could be used to compare urban and rural hospitals but the comparison needs to be carefully planned a priori to avoid drawing misleading conclusions.
Response: According to the reviewer's comment, we have removed the table 4 and have heeded the accompanying advice as per the above response.
Comment 4: The following additional issues could be addressed in a detailed statistical analysis plan: (1) Patients can have multiple entries in the study if presenting more than 30 days after initial enrollment, so how will multiple enrollments by the same patient be handled in analysis, bearing in mind that data from multiple enrollments by the same patient will be correlated?
Response: We thank the reviewer for the valuable advice. Indeed, we recognize the potential for patients to be enrolled in this study more than once. The following considerations have been made within the design and analysis plan. First, given the "acute" diagnosis and care purpose of the emergency department assessment, the primary analysis will focus on each presentation and subsequent 30-day outcome period (i.e. episode of care). Re-presentations within the 30-days will be considered as an outcome and those occurring beyond 30 days will be considered a new episode of care. Second, in order to report appropriate confidence intervals around the estimates of baseline characteristics, they will be reported for the entire "per episode of care" cohort and for the "individual patient cohort" (i.e. with the subsequent representations omitted). We respectfully hope our answer satisfy the reviewer.
(2) Continuous variables, such as heart rate and blood pressure are likely to have non-linear associations with outcome. It would be wise to pre-specify how these variables will be analysed and consider categorising them prior to analysis.
Response: We agree that such parameters have non-linear associations with outcome, but the primary analysis will not seek to correlate these parameters with outcome. Subsequent development of risk prediction scoring systems will require categorizing these continuous variables and spline techniques will be used to explore these associations within this cohort, since prior evidence of such relationships has not been well documented in the literature for Chinese patients. The planning for developing risk prediction scoring systems is discussed in the Discussion section of the revised manuscript because we want to keep the number of hypothesis tests be minimum according to your suggestion. We respectfully hope our answer satisfy the reviewer.
(3) The development of a usable risk-prediction model is likely to involve incorporation of clinical judgement, for example in deciding whether a predictor variable has a clinically credible association or one that is highly dependent on referral pathways. It would be worth planning in advance how clinical judgement will be used in the development of risk prediction models.
Response: We thank the reviewer for pointing out it. Clinical judgement is notoriously difficult to document and thus the translational utility of risk scores reliant on clinical judgement would be limited. Although the development of risk prediction models remains one of the aims of this project, the primary analysis will focus on the hospital level measures that are best correlated with outcome. When addressing the risk prediction models, the risk modeling will take the approach of using objective measures to develop risks scoring that provides a positive and negative likelihood ratio. In doing so, this approach will have greater clinical applicability, and permit a Bayesian approach that builds on clinical judgement. However, this remains a future goal of this work and is now discussed in the Discussion section of the revised manuscript.
(4)I realise that there is little opportunity to change the study design at this stage but it would be worth considering the potential impact of limiting inclusion to those providing informed consent. Is this restriction really necessary? Would it be possible for members of the care team to collect anonymised data? The study does not appear to involve changing patient care, so if it could be designed without the need to use personal identifiable data then it could be ethically undertaken without requiring patient consent, especially if information about the study and the opportunity to opt out were made available.
Exclusion of those unable or unwilling to provide informed consent could be a significant limitation since these people are likely to be systematically different to those able and willing to provide consent.
Response: We thank the reviewer for the valuable advice. We realize that requiring consent may introduce selection bias. However, this study has been designed to adhere to the highest ethical standards. The reasons why we need patients to providing informed consent are that: quite a number of the EDs in China are not yet equipped with electronic medical records systems, not to mention the structured data collection; handwritten medical records are always concise; most of the variables about demographic characteristic, medical history, risk factors and follow-up data cannot be abstracted from medical records. Therefore, we feel acquiring informed consent to obtain this information through interviews with patients in Chinese emergency departments represents good ethical practice. It is not anticipated that requiring consent will introduce a substantial bias, and a screening logs will be kept to assess this. We respectfully hope our answer satisfy the reviewer.
VERSION 2 -REVIEW

REVIEWER
Steve Goodacre University of Sheffield, UK REVIEW RETURNED 06-Nov-2017
GENERAL COMMENTS
Thank you for the opportunity to review the revised paper. The dates of recruitment have been clarified. Recruitment is now complete but follow-up data is in progress so the protocol is eligible for publication. Table 4 has appropriately been removed and the authors have provided some clarification of the plan of analysis. This is fine for descriptive analysis but I would strongly recommend drawing up a detailed statistical analysis plan before any hypothesis testing is undertaken or any attempt is made to develop a risk-prediction model. Hypothesis tests in particular need to be clearly stated (and recorded) a priori so that readers know they have been planned on the basis of a strong rationale rather than arising as a result of trawling the data. The authors may struggle to get their findings published in a reputable journal if they are unable to show that hypothesis testing was planned before analysis was undertaken.
I would also like to clarify a couple of the issues I raised that have been addressed by the authors: 1. It is now clear that analysis will be per episode rather than per patient. This is fine but a high quality analysis would need to take into account that episodes involving the same patient will be correlated. I assume this issue can be handled in generalised estimating equations by including clustering by patient in the analysis.
2. Apologies for the lack of clarity in my comment about clinical judgement. What I was referring to here was the use of clinical judgement in developing a risk-prediction model (i.e. in choosing which variables to include in the model and how to combine them).
My experience of developing similar models is we often intend that the process should be entirely statistical (with variables being included purely on the basis of association with outcome) but then find that judgements need to be made around issues such as interactions between variables and thresholds used. This can be done through an unstructured ad hoc process but is much more convincing when it is planned in advance. For example, you could include a phase in the analysis when a clinical expert panel reviews the developing model and determines issues such as whether variables with unexpected associations are included, how continuous variables are categorised and whether interactions between variables are taken into account. This can help to ensure a model is clinically credible and usable.
I offer these comments for advice in relation to the future publications likely to arise from this work. There is no need to address them in a revision of the protocol.
VERSION 2 -AUTHOR RESPONSE
Response: Thanks very much for your kind advice. We draw up a more detailed statistical analysis plan in the Methods section of the manuscript.
I would also like to clarify a couple of the issues I raised that have been addressed by the authors: 1.It is now clear that analysis will be per episode rather than per patient. This is fine but a high quality analysis would need to take into account that episodes involving the same patient will be correlated. I assume this issue can be handled in generalised estimating equations by including clustering by patient in the analysis.
Response: Thank you for pointing out it. We also agree that the correlation between the same patient could be handled by generalized estimating equations. We added this analysis in the statistical analysis section.
2. Apologies for the lack of clarity in my comment about clinical judgement. What I was refrring to here was the use of clinical judgement in developing a risk-prediction model (i.e. in choosing which variables to include in the model and how to combine them). My experience of developing similar models is we often intend that the process should be entirely statistical (with variables being included purely on the basis of association with outcome) but then find that judgements need to be made around issues such as interactions between variables and thresholds used. This can be done through an unstructured ad hoc process but is much more convincing when it is planned in advance.
For example, you could include a phase in the analysis when a clinical expert panel reviews the developing model and determines issues such as whether variables with unexpected associations are included, how continuous variables are categorised and whether interactions between variables are taken into account. This can help to ensure a model is clinically credible and usable.
Response: Thanks very much for your kind advice. We will pay attention to the clinical judgement in developing risk-prediction models.
